Michael Baltezor
25Patents
9h-index
24Co-inventors
75Inventor score
Filing activity: May 6, 1993 → Jan 29, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5286497A | Diltiazem formulation | Human Necessities | 108 | Expired |
| US5439689A | Diltiazem formulation | Human Necessities | 98 | Expired |
| US5470584A | Diltiazem formulation | Human Necessities | 54 | Expired |
| US9814685B2 | Taxane particles and their use | Performing Operations; Transporting | 35 | Active |
| US9918957B2 | Methods for making compound particles | Performing Operations; Transporting | 21 | Active |
| US10507195B2 | Taxane particles and their use | Performing Operations; Transporting | 16 | Active |
| US10729673B2 | Taxane particles and their use | Performing Operations; Transporting | 11 | Active |
| US10398646B2 | Methods for treating lung disorders | Human Necessities | 10 | Active |
| US10507181B2 | Methods for treating lung disorders | Human Necessities | 10 | Active |
| US10993927B2 | Taxane particles and their use | Performing Operations; Transporting | 1 | Active |
| US11123322B2 | Taxane particles and their use | Performing Operations; Transporting | 1 | Active |
| US11058639B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US12029818B2 | Lapatinib particles and uses thereof | Human Necessities | 0 | Active |
| US11738014B2 | Niraparib particles and uses thereof | Human Necessities | 0 | Active |
| US11523983B2 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | Emerging Cross-Sectional Technologies | 0 | Active |
| US11737972B2 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | Emerging Cross-Sectional Technologies | 0 | Active |
| US11931368B2 | Glucocorticoid “nintedanib” particles and their use | Human Necessities | 0 | Active |
| US9205109B2 | Copper salts of ion exchange materials for use in the treatment and prevention of infections | Emerging Cross-Sectional Technologies | 0 | Active |
| US11918691B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11104663B2 | Ciprofloxacin polymorph and its use | Human Necessities | 0 | Active |
| US12329858B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11160754B2 | Methods for treating lung disorders | Human Necessities | 0 | Active |
| US11738029B2 | Rucaparib particles and uses thereof | Human Necessities | 0 | Active |
| US12128131B2 | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | Emerging Cross-Sectional Technologies | 0 | Active |
| US11583499B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.